Recursion Pharmaceuticals, Inc. Share Price & Technical Analysis
RXRX · $3.01 (-3.22%)
Healthcare / Biotechnology
$3.01
-3.22%
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenoma…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-14% return in May, 21% avg return in past 3 year May month.
-23% return in 2026, 28% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | -10% | -11% | 13% | -14% | – | – | – | – | – | – | – | -23% |
| 25 | 4% | 9% | -33% | 6% | -26% | 21% | 18% | -16% | 7% | 15% | -18% | -9% | -23% |
| 24 | -3% | 42% | -25% | -22% | 6% | -11% | 9% | -11% | 2% | -3% | 11% | -6% | -10% |
| 23 | 6% | -2% | -17% | -27% | 83% | -13% | 91% | -37% | -12% | -31% | 31% | 46% | 116% |
| 22 | -31% | -6% | -33% | -14% | -2% | 33% | 5% | 27% | 3% | -3% | -12% | -17% | -51% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.64B
P/E ratio
—
52W high
$7.18
52W low
$2.77
Volume
1,40,23,416
Beta
1.05
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Recursion Pharmaceuticals, Inc. share price today?
- Recursion Pharmaceuticals, Inc. (RXRX) last traded around $3.01 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does RXRX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for RXRX. Download the app for real-time alerts.
- How can I analyze Recursion Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.